Therefore, METTL3 promotes the migration of monocyte-derived macrophages and Aβ clearance by regulating the Dnmt3a-Atat1 axis, ultimately alleviating AD, highlighting that targeting METTL3 is a promising target for AD treatment in the future. Here, DNMT3A is linked to Alzheimer disease.